VBI Vaccines (VBI Vaccines) EPS (Basic)

: $-9.41 (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

VBI Vaccines's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.41.

VBI Vaccines's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.41.

VBI Vaccines's EPS without NRI for the three months ended in Dec. 2023 was $-0.60. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -5.61.

During the past 3 years, the average EPS without NRI Growth Rate was 13.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 25.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, VBI Vaccines's highest 3-Year average EPS without NRI Growth Rate was 55.60% per year. The lowest was -218.30% per year. And the median was 9.05% per year.

VBI Vaccines EPS (Basic) Historical Data

The historical data trend for VBI Vaccines's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VBI Vaccines Annual Data

Trend

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

-13.80

-6.30

-8.10

-13.16

-6.03

VBI Vaccines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)																-2.45	-3.22	-5.18	-1.01	-0.01

VBI Vaccines EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

VBI Vaccines's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-92.836	-	0)	/	15.572
	=	-5.96

VBI Vaccines's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.013	-	0)	/	23.919
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.41

VBI Vaccines (NAS:VBIV) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

VBI Vaccines EPS (Basic) Related Terms

Thank you for viewing the detailed overview of VBI Vaccines's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

VBI Vaccines (VBI Vaccines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (NAS:VBIV) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

LO9A:Germany

Address

160 Second Street, Floor 3, Cambridge, MA, USA, 02142

Website

https://www.vbivaccines.com

VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.

Executives

Steven Gillis	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Vaughn B Himes	director	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Robert Dillman	officer: Chief Commercial Officer	C/O VBI VACCINES INC., 160 SECOND STREET, FLOOR 3, CAMBRIDGE MA 02142
Nell Beattie	officer: Director, Corp Development/IR	222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Linda Bain	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Damian Braga	director	222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Francisco Diaz-mitoma	officer: Chief Medical Officer	222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Christopher Mcnulty	officer: CFO and Head of BD	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeff Baxter	director, officer: President and CEO	C/O VBI VACCINES INC.,, 222 THIRD STREET, STE 2241, CAMBRIDGE MA 02142
Joanne Cordeiro	director	171 SWANTON STREET, UNIT 48, WINCHESTER MA 01890
Blaine H. Mckee	director	C/O HART, 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
Tomer Kariv	director	C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003